Micrima announces appointment of CTO for ground breaking breast imaging technology
13 August 2015
Micrima, the Bristol-based developer of the innovative MARIA radiowave breast imaging system, backed by Technology Venture Partners LLP, Swarraton Partners LLP, the Angel Co-Fund and a growing list of business angels, has appointed Dr Peter Bannister as Chief Technology Officer. Dr Bannister holds a doctorate in Medical Image Analysis from the University of Oxford and joins Micrima from Alesi Surgical where he held the post of Head of Operations, responsible for R&D, manufacturing and distribution.
While at Oxford, Dr Bannister was Senior College Lecturer in Engineering Science (Keble College) and one of the original developers of the FMRIB Software Library (FSL), which remains the gold standard for functional neuroimaging analysis. He is also Chairman of the Institution of Engineering and Technology (IET) Healthcare Technologies Network, which represents the technical and professional interests of the Institution’s international membership working in biomedical and healthcare engineering fields.
On joining Micrima, Dr Bannister said: “I am very excited by this unique opportunity to play a role in the development of a truly novel medical imaging modality where there is both a genuine need for the technology as well as a growing body of robust clinical evidence generated for the system. With the team in Bristol, I look forward to addressing numerous opportunities to evolve the MARIA system so that it delivers increased levels of information that can aid radiologists in the early and accurate diagnosis of breast cancer.”
Roy Johnson, Micrima’s Executive Chairman, commented, “I am delighted that we have been able to secure Peter in this new role. With CE mark now on board, Micrima is strengthening the senior team and Peter comes in with exactly the right background to help accelerate our development programmes and make the MARIA imaging system the game-changer it promises to be.”
Micrima was founded in 2006 to develop and commercialise radiowave radar breast imaging technology, initially pioneered at the University of Bristol in the UK. The company’s MARIA system received European regulatory approval in 2015 and is currently deployed in pre-commercialisation clinical trials based at several breast cancer imaging centres throughout the UK.
For further information, please contact Micrima Executive Chairman Roy Johnson on 07769 883882
NOTES TO EDITORS:
Technology Venture Partners LLP (www.techvp.co.uk) is a venture capital fund management company based at the Innovation Centre at Bristol & Bath Science Park. TVP is authorised and regulated by the Financial Conduct Authority.
Swarraton Partners (www.swarraton.com) is a venture capital firm investing in European early stage technology companies based on world class IP.